Genentech Reports Phase III Study of Tecentriq in Women with Advanced-stage Ovarian Cancer Fails to Meet Endpoint

Jul 16, 2020 | Challenging Results, Gynecology, News, Oncology

Genentech Reports Phase III Study of Tecentriq in Women with Advanced-stage Ovarian Cancer Fails to Meet Endpoint

Genentech reported results from the Phase III IMagyn050 study which evaluated the addition of Tecentriq (atezolizumab) to Avastin (bevacizumab), paclitaxel and carboplatin for the front-line treatment of women with newly-diagnosed advanced-stage ovarian cancer who are undergoing neoadjuvant or adjuvant therapy. The trial did not meet its primary endpoint of progression-free survival (PFS). Data for the overall survival (OS) co-primary endpoint are currently immature and follow-up will continue until the next planned analysis. Results from IMagyn050 will be further evaluated in order to inform the Tecentriq gynecological development program.

The IMagyn050 study is being conducted in collaboration with The GOG Foundation, Inc. (GOG Foundation) [GOG-3015] and the European Network of Gynaecological Oncological Trial groups (ENGOT) [ENGOT OV-39].

About Tecentriq (atezolizumab)

Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells.

About Avastin (bevacizumab)

Avastin is a prescription-only medicine that is a solution for intravenous infusion. It is a biologic antibody designed to specifically bind to a protein called VEGF that plays an important role throughout the lifecycle of the tumor to develop and maintain blood vessels, a process known as angiogenesis. Avastin is designed to interfere with the tumor blood supply by directly binding to the VEGF protein to prevent interactions with receptors on blood vessel cells. The tumor blood supply is thought to be critical to a tumor’s ability to grow and spread in the body (metastasize).

About ovarian cancer

According to the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women. This year, an estimated 21,000 women will be diagnosed with ovarian cancer and 14,000 will die from the disease. Ovarian cancer remains the leading cause of death from any gynecological malignancy, as the majority of patients are not diagnosed until they present with already advanced-stage disease, resulting in a 5-year survival rate of less than 30%.

Source: Genetech

0 Comments

Pin It on Pinterest